Introduction
============

Fragile X Syndrome, FXTAS, and FXPOI are X-linked disorders that arise from expansions in a CGG-repeat region in the 5′-UTR of the *FMR1* gene. Normal *FMR1* alleles contain 6--54 repeats, expansions from 55 to 200 repeats are considered "premutations" and all larger repeat sizes are known as the "full mutations." Individuals with a premutation may develop the adult-onset neurodegenerative disorder known as FXTAS, while women carrying the premutation are at risk for FXPOI. Only the full mutation leads to FXS, which is a common cause of inherited intellectual disability and autism ([@B27]). *FMR1* premutations result in overproduction of toxic, expanded mRNAs that contribute to the development of FXPOI and FXTAS pathology ([@B38]; [@B16]). Full mutations lead to DNA and repressive histone methylation of the *FMR1* locus ([@B37]; [@B14]; [@B6], [@B5]; [@B21]). Thus FXS derives from the loss of *FMR1* mRNA and protein FMRP. We and others have identified four non-coding transcripts with abnormal expression in response to Fragile X repeat expansions at the *FMR1* locus ([@B22]; [@B17]; [@B28]), but their role in FXS/FXTAS/FXPOI phenotypes remains to be determined.

The vast majority of the human transcriptome is comprised of either long \[\>200 nucleotides (nt)\] or short ncRNAs ([@B4]; [@B2]; [@B8]). While short ncRNAs typically regulate gene expression through posttranscriptional mechanisms or by interfering with translation ([@B32]; [@B10]), lncRNAs (which can be many kilobases long) often act in *cis* or *trans* to regulate gene expression at their locus of origin or elsewhere in the genome, respectively. Evidence suggests that lncRNAs perform scaffolding functions by recruiting epigenetic complexes or ribonucleoproteins that cause chromatin remodeling ([@B41]). Other lncRNAs act post-transcriptionally by targeting mRNAs or translational machinery. Regardless of the mechanism, a growing body of evidence implicates lncRNAs in a myriad of normal cellular functions such as DNA damage response and mitosis ([@B39]; [@B42]; [@B15]; [@B20]; [@B41]) and in diseases, such as cancer ([@B13]).

Recent attention has focused more specifically on the role of lncRNAs in neurodevelopmental programs and diseases of the nervous system. For example, lncRNAs are involved in the differentiation of neural cell types, and synaptic signaling and maturation ([@B24]; [@B30]). In addition, both short and long ncRNAs are known to be involved in Prader--Willi syndrome, which is a developmental disorder caused by paternal deletion of a maternally imprinted region and can present with metabolic dysregulation including circadian rhythm defects ([@B34]; [@B7]; [@B29]). Both syndromic and non-syndromic ASD susceptibility loci also contain aberrantly expressed lncRNAs that may contribute to disease ([@B40]; [@B45]). Dysfunction of lncRNAs has also been linked to pathogenesis of neurodegenerative disorders including Alzheimer's disease ([@B11]) and spinocerebellar ataxia type 7, another repeat expansion disorder ([@B36]). In sum, there is a growing body of evidence supporting the involvement lncRNAs in both the normal and diseased nervous system, spurring further mechanistic inquiries.

*FMR4*, an untranslated, antisense lncRNA originating at the *FMR1* gene locus was shown to have anti-apoptotic functions in HEK293T and HeLa cells but to have no effect on expression of *FMR1* ([@B17]). Here, we describe *FMR4*'s function as a regulator of gene expression in *trans* by identifying mRNA expression changes induced by *FMR4*. In particular, these effects in HEK293T cells are mirrored by discordant developmental regulation between *FMR4* and one of its targets, *MBD4*, in hNPCs.

Materials and Methods {#s1}
=====================

HEK293T Cell Culture, Transfection, and RNA Extraction
------------------------------------------------------

HEK293T cells were cultured in DMEM with 10% FBS. In overexpression experiments, cells were transfected with pcDNA3.1-FMR4 or the empty pcDNA3.1 control vector using Lipfectamine 2000CD. For knockdown experiments, the siRNA FMR4(C) ([@B17]), versus Silencer Negative Control siRNA \#1 (Ambion) were used with the Lipofectamine RNAiMAX transfection reagent, according to manufacturer's instructions (Invitrogen). For microarray experiments, 1 × 10^6^ cells were plated and transfected with 0.5 μg plasmid or 40 nM siRNA on the same day, and incubated for 6 or 24 h after transfection. For validation, *FMR4* was knocked down using two sequential siRNA transfections over 72 h. RNA was extracted using Trizol (Invitrogen) and the RNeasy Mini Kit, and treated with DNAse on-column using the RNAse-free DNAse Set (Qiagen) according to manufacturer's instructions.

Microarray Hybridization and Analysis
-------------------------------------

At 6 or 24 h post transfection, RNA was extracted and samples were submitted to the Hussman Institute for Human Genomics Center for Genome Technology for microarray analysis using Affymetrix Human Gene 2.0 ST Arrays. Total RNA samples were first prepared using the Ambion WT Expression Kit (cat\# 4411974). Briefly, the kit generates sense-strand cDNA from total RNA using a reverse transcription priming method that specifically primes non-ribosomal RNA, including both poly(A) and non-poly(A) mRNA. Next, samples are fragmented and labeled using the Affymetrix GeneChip WT Terminal Labeling Kit (cat\# 902280). Final yield was hybridized onto the array, washed and stained using the Affymetrix GeneChip Hybridization, Wash, and Stain Kit (cat\# 900720). Arrays were scanned using GeneChip Scanner 3000 7G system. Background subtraction, GC-RMA normalization and quality control were performed using the Affymetrix GeneChip Command Console Software and the bioconductor package from R. Data have been archived in the Gene Expression Omnibus at the National Center for Biotechnology Information, and assigned the accession number GSE70817.

cDNA Synthesis and Quantitative Real-Time PCR (qPCR)
----------------------------------------------------

cDNA was synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) with 500 ng of total RNA per reaction. Gene-specific FMR4 cDNA was primed separately ("FMR4 RT": ATTGCTGGCAGTCGTTTCTT), in order to specifically detect the antisense transcript and prevent capture of overlapping sense transcripts arising from that genomic region. Random hexamer-primed cDNA libraries were used for detection of all other genes. FMR4 RNA expression was quantified using SYBR Green quantitative real-time PCR (qPCR) with the following primers, validated by melting curve: "FMR4 FW" -- ACCAAACCAAACCAAACCAA and "FMR4 REV" -- GTGGGAAATCAAATGCATCC. Commercially available TaqMan probes (Invitrogen) were used for all other transcripts (MBD4, cat\# Hs00187498_m1; FMR1, cat\# Hs00924547_m1; MALAT1, cat\# Hs01910177_s1). The endogenous control was glyceraldehyde 3-phosphate dehydrogenase (GAPDH, cat\# 4326317E) where necessary, and data were analyzed by the ΔΔCt method. For polyA detection, cDNA was synthesized from 1 μg total RNA using the High Capacity cDNA kit and oligodT primers at 50 nM final concentration. In the noRT control, we omitted the reverse-transcriptase enzyme from the cDNA synthesis reaction. Reverse transcription products were amplified using qPCR as described above and visualized on a 1.5% agarose gel.

Human Neural Precursor Cell (hNPC) Culture, Differentiation, and Viral Transduction
-----------------------------------------------------------------------------------

hNPCs used in this study were derived from human fetal brains collected from third trimester aborted fetuses received from the Birth Defects Research Lab at the University of Washington in Seattle. This work was classified as "Non-Human Subject Research" by the Human Subject Research Office at the University of Miami, and therefore was not subject to Institutional Review Board approval. Briefly, brain tissues were dissected and dissociated using the trypsin-based Neural Tissue Dissociation Kit (Miltenyi Biotec, cat \#130-093-231). Five million single cells were seeded into each 75-mm tissue culture flask in proliferation media supplemented with B27 (1X of proprietary formula), human Epidermal Growth Factor (hEGF) at 20 ng/mL, human Fibroblast Growth Factor (hFGF) at 10 ng/mL, heparin at 20 ug/mL, GlutaMax (1X, Gibco), and Primocin at 0.1 mg/mL (InvivoGen). Neural stem cells formed neurosphere colonies after approximately 7 DIV, while other cells remained in suspension as single cells or formed a monolayer on the flask surface. Neurospheres can be maintained as such in suspension for several months using proliferation media, or hNPCs can be differentiated, forming a mixture of neurons and astrocytes. Neurospheres were transduced with a lentiviral vector expressing *FMR4* (pLentiCMV/TO-mCherry-FMR4) or the control vector (pLentiCMV/TO-mCherry), and collected for qPCR analysis after 2 days. To differentiate, neurospheres are dissociated into single cells with Accutase and cultured in Advanced DMEM/F12 media without hFGF or hEGF, but with Bottenstein's N2 at 1X (Invitrogen, proprietary formula), 2.5% fetal bovine serum, heparin at 20 μg/mL, GlutaMax (1X, Gibco) and Primocin at 0.1 mg/mL (InvivoGen).

Subcellular Fractionation
-------------------------

Neurospheres were collected by centrifugation at 250 × *g* in order to form 50 μL pellets. Pellets were washed with PBS and fractionated with the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, cat\# 78835) according to manufacturer's instructions. Briefly, cells were sequentially lysed and centrifuged to first separate pelleted nuclei from cytoplasm, then to separate chromatin from nucleoplasmic components. RNA was extracted from solid chromatin with 1 mL of Trizol, and with 0.75 mL Trizol LS for every 0.25 mL of liquid fraction. cDNA prepared using random primers was used for TaqMan qPCR (*MALAT1*, *GAPDH*, and *FMR1*), while gene-specific priming and SYBR Green was used for *FMR4* as noted above. In each case, starting material for cDNA reactions was 2 μL total RNA (not equal mass of RNA), to enable comparison of absolute quantities of each transcript between compartments. Relative quantification (RQ) for each transcript in each compartment was calculated from Cq values by qPCR. Individual fraction RQ values were normalized to the total detected amount for each transcript.

Results
=======

*Fmr4* Induces Genome-Wide Changes in Gene Expression
-----------------------------------------------------

Previous studies of the 2.4 kb antisense lncRNA *FMR4* described no *cis-*regulation of *FMR1* ([@B17]); therefore we hypothesized that *FMR4* would regulate gene expression in *trans*, which is a well-documented function of other lncRNAs ([@B31]; [@B18]; [@B25]). In order to comprehensively measure gene regulation in response to *FMR4* at the mRNA level, we treated HEK293T cells with either an siRNA against *FMR4*, a scrambled control siRNA (knockdown), pcDNA3.1-*FMR4*, or the empty pcDNA3.1 vector (overexpression) and processed for microarray hybridization after 6 or 24 h. Using LIMMA, a linear modeling approach ([@B35]), we identified differential expression of over 3,700 genes between *FMR4* knockdown, overexpression and their respective control conditions, and characterized the pattern of target gene expression relative to *FMR4*. To this end, we used the Cluster Affinity tool of TIGR MultiExperiment Viewer to identify genes with opposite behavior in the knockdown condition compared to the overexpression condition. This strategy narrowed our focus to the 238 transcripts represented in **Figure [1A](#F1){ref-type="fig"}** and Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}, which are further classified by whether they are concordant or discordant with respect to *FMR4* changes. This analysis yielded 155 and 83 target genes with concordant and discordant changes in mRNA expression relative to *FMR4*, respectively. These data support the idea that *FMR4* is a regulator of gene expression through *trans*-activity.

![**Microarray analysis of mRNA expression changes in response to *FMR4* knockdown and overexpression reveal *trans*-regulatory targets. (A)** Microarray analysis of HEK293T cells with *FMR4* overexpression or knockdown (*n* = 3). LIMMA analysis and Cluster Affinity identified genes concordantly or discordantly regulated compared to *FMR4*. **(B)** *FMR4* was knocked down with siRNA in HEK293T cells in order to validate changes in a putative *FMR4*-sensitive gene identified by microarray **(C)**. (*n* = 6, \**p* \< 0.05 by Student's *t*-test).](fgene-06-00263-g001){#F1}

Pathway Analysis and *FMR4* Target Validation
---------------------------------------------

We then analyzed the cohort of concordant and discordant *FMR4*-responsive genes with GeneGo Metacore (**Tables [1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**). Cell cycle regulation and apoptosis were highly ranked biological processes affected by *FMR4*, which is consistent with our earlier findings ([@B17]). Additionally, *FMR4*-sensitive genes are enriched in developmental processes in general and neurodevelopmental processes in particular (e.g., adrenergic and opioid signaling, Wnt pathway, cytoskeletal elements, synaptogenesis). Informed by the pathway analysis and previous insights into *FMR4*'s function, we used HEK293T cells with *FMR4* knocked down by sequential siRNA transfections (**Figure [1B](#F1){ref-type="fig"}**) to validate a 28% increase in methyl CpG-binding domain (*MBD4*; **Figure [1C](#F1){ref-type="fig"}**).

###### 

Top GeneGo pathways represented by *FMR4*-responsive genes identified by microarray analysis.

  Category          GeneGo pathway                                                     *p*-value
  ----------------- ------------------------------------------------------------------ -----------
  Cell adhesion     Chemokines and adhesion                                            0.10161
                    Integrin-mediated cell adhesion and migration                      0.11458
  Cell cycle        Regulation of G1/S transition (part 2)                             0.00000
                    Nucleocytoplasmic transport of CDK/Cyclins                         0.03480
                    Spindle assembly and chromosome separation                         0.08019
  Development       Mu-type opioid receptor signaling via beta-arrestin                0.00000
                    S1P1 receptor signaling via beta-arrestin                          0.00000
                    Beta-adrenergic receptors transactivation of EGFR                  0.00000
                    Ligand-independent activation of ESR1 and ESR2                     0.00001
                    Gastrin in cell growth and proliferation                           0.00002
                    Alpha-2 adrenergic receptor activation of ERK                      0.00002
                    Regulation of epithelial-to-mesenchymal transition (EMT)           0.04670
                    Lipoxin inhibitory action on PDGF, EGF, and LTD4 signaling         0.08717
                    A3 receptor signaling                                              0.11683
  Immune response   Oncostatin M signaling via MAPK in mouse cells                     0.00000
                    Oncostatin M signaling via MAPK in human cells                     0.00000
                    IL-15 signaling                                                    0.00002
                    Histamine H1 receptor signaling in immune response                 0.02758
  Transport         RAN regulation pathway                                             0.04453
  N/A               Inhibitory action of Lipoxin A4 on PDGF, EGF, and LTD4 signaling   0.08485

###### 

Top GeneGo process networks represented by *FMR4*-responsive genes identified by microarray analysis.

  Category          GeneGo process networks                                      *p*-value
  ----------------- ------------------------------------------------------------ -----------
  Apoptosis         Death domain receptors and caspases in apoptosis             0.02682
  Cell adhesion     Platelet aggregation                                         0.02999
                    Leucocyte chemotaxis                                         0.04076
  Cell cycle        G1/S Interleukin regulation                                  0.00000
                    G1-S Growth factor regulation                                0.00002
  Cytoskeleton      Actin filaments                                              0.00022
                    Actin filaments                                              0.03088
  Development       Hemopoiesis, erythropoietin pathway                          0.00000
                    Neurogenesis and synaptogenesis                              0.08499
                    Neuromuscular junction                                       0.11290
                    Wnt/beta-catenin, notch, VEGF, IP3, and integrin signaling   0.11674
  DNA Damage        Checkpoint                                                   0.00006
  Immune response   BCR pathway                                                  0.00008
  Inflammation      MIF signaling                                                0.00000
                    IL-2 signaling                                               0.00003
                    Protein C signaling                                          0.06668
                    Kallikrein--kinin system                                     0.09179
  Reproduction      FSH-beta signaling pathway                                   0.00001
  Signal            CREM pathway                                                 0.00002
  Transduction      Neuropeptide signaling pathways                              0.01407

Developmental Regulation of Gene Expression by *FMR4* in hNPCs
--------------------------------------------------------------

To investigate the putative role of *FMR4* in neurodevelopment and Fragile X-associated neurological disorders, we used an *in vitro* model system consisting of human fetal-derived neurospheres (hNSs). These cells can be maintained as precursor in hNSs, or induced to differentiate into a mixed culture of early neurons and glia (see Materials and Methods). This system has the advantage of being a primary culture of human brain cells (critical for studying a primate-specific transcript *in vitro*) without the need for reprogramming, as would be the case with embryonic or induced pluripotent stem cells. We focused on the relationship between *FMR4* and its putative target gene, *MBD4*, which we identified by microarray analysis. *MBD4* is a transcriptional repressor involved in DNA repair ([@B1]; [@B19]). Expression of *MBD4* developmentally regulates several tissues ([@B33]; [@B43]), and its aberrant expression in hippocampal GABAergic neurons in psychiatric disease may be linked to abnormal differentiation in these cells ([@B3]).

The *FMR1* locus is crucial to normal brain development; thus, we wanted to determine whether *FMR4* expression is dependent on developmental stage. We extracted RNA from undissociated hNS \["0 days *in vitro*" (DIV)\] and cultured cells from dissociated hNS up to five DIV in differentiation media. At both time points, we measured *FMR4* expression as well as that of *FMR1*, to determine whether these transcripts are independently regulated. We observed that *FMR4* expression is significantly decreased in differentiating cells at 5 DIV while *FMR1* is increased at the same time point (**Figure [2A](#F2){ref-type="fig"}**). We then measured *MBD4* and found that it is also developmentally regulated. As indicated by the microarray analysis, *MBD4* was increased at a time point when *FMR4* expression is low (**Figure [2A](#F2){ref-type="fig"}**). We also observed changes in expression level of other *FMR4* target genes in undifferentiated, proliferating hNPCs transduced with an mCherry-tagged lentiviral vector expressing *FMR4* (Supplementary Figure [S2A](#SM1){ref-type="supplementary-material"}). We found that *FMR4* overexpression significantly upregulated two putative targets, the deubiquitinase *YOD1* and the G-protein subunit *GNG12*, and downregulated the ribonucleotide reductase *RRM2* (Supplementary Figure [S2B](#SM1){ref-type="supplementary-material"}). These data corroborate our finding that *FMR4* regulates gene expression in *trans*.

![**Expression of *FMR4* and its target *MBD4* during differentiation of hNPCs may be related to chromatin-modulatory function of the lncRNA. (A)** Comparison of RNA expression between proliferating neurospheres (0 DIV) and differentiating hNPCs (5 DIV) revealed increased *FMR1* and decreased *FMR4* after 5 days of differentiation (*n* = 5, \**p* \< 0.05 by Student's *t*-test). As predicted, the putative *FMR4* target gene *MBD4* was upregulated with decreased *FMR4*. Subcellular fractionation of hNPCs with subsequent qPCR detection confirmed the cytoplasmic localization of mRNAs such as **(B)** *GAPDH* and *FMR1*. *MALAT1* **(C)**, known to be associated to nuclear speckles, was significantly enriched in the nucleus and chromatin compared to cytoplasm. *FMR4* RNA **(C)** was largely localized to chromatin. (*n* = 5, \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 by One-way ANOVA with Tukey HSD).](fgene-06-00263-g002){#F2}

Molecular Mechanisms of *FMR4*
------------------------------

To better understand the molecular role of *FMR4*, we performed subcellular fractionation of hNS. As expected, *GAPDH* and *FMR1* mRNA were highest in the cytoplasmic fraction (87.6 and 67.0%, respectively) where they are translated ([@B9]) (**Figure [2B](#F2){ref-type="fig"}**). Some lncRNAs are expressed predominantly in the nucleus. A well-known example of this is the lncRNA *NEAT2/MALAT1* ([@B12]). We measured this transcript as a positive control for nuclear transcripts, and found it enriched in the nucleoplasm (41.6%) and chromatin (54.0%) relative to the cytoplasm (**Figure [2C](#F2){ref-type="fig"}**). *FMR4* RNA was primarily localized (73.4%) to chromatin (**Figure [2C](#F2){ref-type="fig"}**), which is consistent with a transcriptional regulatory function of *FMR4*.

Since RNA polyadenylation frequently targets mature RNA for export into the cytoplasm ([@B44]); many lncRNAs are not polyadenylated. Therefore, to establish whether *FMR4* can be polyadenylated, we performed first-strand cDNA synthesis with oligodT primers, thereby capturing polyadenylated transcripts from total hNS RNA. We observed *via* qPCR that in addition to *FMR1* and *GAPDH* mRNAs (which are expected to be polyadenylated), a detectable portion of *FMR4* is also polyadenylated (Supplementary Figure [S3](#SM1){ref-type="supplementary-material"}). These data suggest that a fraction of *FMR4* may be stabilized by polyadenylation; this would increase the molecule's half-life and permit its diffusion to distant genomic loci.

Discussion
==========

Loss of *FMR1* mRNA and FMRP function has been widely studied, but there is relatively little known about ncRNA encoded by the locus. Here we show that one such ncRNA, *FMR4*, may regulate mRNA expression genome-wide *via* a developmentally regulated transcriptional mechanism, thereby impacting important biological processes.

Similar to *FMR4*, *trans*-acting lncRNAs \[such as *HOTAIR*, *MALAT1*, and *GAS5* ([@B31]; [@B18]; [@B25])\] affect loci far from their genomic locus of origin. In this study, we confirmed that knockdown and overexpression of *FMR4* causes changes in genes involved in proliferation and differentiation. As a chromatin-associated transcript, *FMR4* may act at the transcriptional level by forming complexes with histone modifying enzymes or by directly targeting mRNA stability, splicing, or editing. It remains to be seen whether these observations are dependent on RNA-protein interactions, and whether they result from direct epigenetic changes or *via* downstream effects.

Our data show that *FMR4* is developmentally regulated in an hNPC model. After 5 days of *in vitro* differentiation, *FMR4* expression is significantly reduced, while that of both *FMR1* and the *FMR4* target gene *MBD4* is increased. Since *FMR4* and *FMR1* do not interact in *cis* but are discordantly expressed with differentiation of hNPCs, the bidirectional promoter responsible for expression of both of these transcripts might be activated in only one direction at a time. An alternative possibility is that *FMR4* RNA is degraded at a higher rate during this period while *FMR1* is not. Nevertheless, it would be interesting to determine whether transcription factors normally regulate this locus as a whole or target each transcript individually. It is also unclear whether the decrease in *FMR4* lncRNA expression contributes to disease in addition to loss of *FMR1*, or is an artifact of the locus-wide, full mutation-induced epigenetic changes causing transcriptional repression. Future studies will be necessary to distinguish between these possible mechanisms and consequences of *FMR4* regulation.

Discordant regulation of *MBD4* and *FMR4* leads us to conclude that *FMR4* regulates expression of genes at distal loci, as the same relationship was identified by our overexpression and knockdown studies. Our independent validation studies confirm this was not due to false positive identification, which is a common problem in genome-wide analyses such as microarray studies. *FMR4*'s localization to the chromatin fraction points to a transcriptional mechanism for this effect, however, studies evaluating the direct binding of *FMR4* to nucleic acids or proteins are warranted. Such studies could suggest a direct role for *FMR4* in specifically regulating *MBD4* and gene expression more broadly, although this cannot be concluded definitively based solely on changes in mRNA levels. We acknowledge that differences in RNA processing or any number of effects downstream of *FMR4* could be responsible for the observed differential gene expression, therefore it would be useful to examine precise interactions between *FMR4* and its targets. Chromatin immunoprecipitation experiments could, for example, establish an interaction between *FMR4* and promoter regions of target genes. Based on the function of other lncRNAs, one could speculate that *FMR4* helps form three-dimensional interactions between distant sequence elements such as promoters and enhancers ([@B23]), and that *FMR4* polyadenylation targets this transcript for further RNA processing ([@B26]). Answering these questions would help our understanding of *FMR4* function in particular and continue the rapid expansion of evidence on the elements that govern lncRNA actions in general.

In this study we have described novel facets of *FMR4* functionality as it relates to neurodevelopment, and suggest that perturbation in the expression of this lncRNA may contribute to pathogenesis of the Fragile X repeat expansion-associated disorders. We report that *trans-*regulatory activity of *FMR4* is corroborated by changes in target gene expression during differentiation of hNPCs. With this new information, we have further developed the evidence supporting the role of primate-specific lncRNAs in complex developmental programs and opened new avenues of research into the causes and therapies for Fragile X-associated neurological disorders.

Author Contributions
====================

VP, CP, DM, KW, DV, and MM contributed to the acquisition, analysis, and interpretation of data. VP, CP, ZZ, JB, VL, JS, and CW made substantial contributions to the conception and design of the work. All authors participated in drafting and/or revising the manuscript for intellectual content, approval for publication and agree to be accountable for all aspects of the work.

Conflict of Interest Statement
==============================

The reviewer Guney Bademci declares that, despite being affiliated with the same institute as the authors Veronica J. Peschansky, Chiara Pastori, Zane Zeier, Dario Motti, Katya Wentzel, Dmitry Velmeshev, Marco Magistri, John L. Bixby, Vance P. Lemmon, José P. Silva, and Claes Wahlestedt, the review process was conducted objectively.

The authors would like to acknowledge Yan Shi, MS, for her help with high content screening assays and Nagi Ayad, Ph.D., for his guidance and critical reading of the manuscript.

**Funding.** This work was supported by the National Institutes of Health (MH084880 to CW, HD057521 to VL and NS059866 to JB), as well as the Lois Pope LIFE Foundation Development Award and the Louis J. Elsas Research Award in Biochemical Genetics to VP.

Supplementary Material
======================

The Supplementary Material for this article can be found online at: <http://journal.frontiersin.org/article/10.3389/fgene.2015.00263>

###### 

Click here for additional data file.

ASD

:   autism spectrum disorder

DIV

:   days *in vitro*

FMRP

:   Fragile X mental retardation protein

FXPOI

:   Fragile X-related primary ovarian insufficiency

FXS

:   Fragile X syndrome

FXTAS

:   Fragile X-associated tremor/ataxia syndrome

hNPCs

:   human neural precursor cells

hNS

:   human neurospheres

lncRNAs

:   long non-coding RNAs

mRNA

:   messenger RNA

ncRNAs

:   non-coding RNAs
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